Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Nowadays, available therapies for MS can help to manage MS course and symptoms, but new therapeutic approaches are required. Stem cell therapy using mesenchymal stem cells (MSCs) appeared promising in diff...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/22/8662 |
| _version_ | 1797547724695928832 |
|---|---|
| author | Agnese Gugliandolo Placido Bramanti Emanuela Mazzon |
| author_facet | Agnese Gugliandolo Placido Bramanti Emanuela Mazzon |
| author_sort | Agnese Gugliandolo |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Nowadays, available therapies for MS can help to manage MS course and symptoms, but new therapeutic approaches are required. Stem cell therapy using mesenchymal stem cells (MSCs) appeared promising in different neurodegenerative conditions, thanks to their beneficial capacities, including the immunomodulation ability, and to their secretome. The secretome is represented by growth factors, cytokines, and extracellular vesicles (EVs) released by MSCs. In this review, we focused on studies performed on in vivo MS models involving the administration of MSCs and on clinical trials evaluating MSCs administration. Experimental models of MS evidenced that MSCs were able to reduce inflammatory cell infiltration and disease score. Moreover, MSCs engineered to express different genes, preconditioned with different compounds, differentiated or in combination with other compounds also exerted beneficial actions in MS models, in some cases also superior to native MSCs. Secretome, both conditioned medium and EVs, also showed protective effects in MS models and appeared promising to develop new approaches. Clinical trials highlighted the safety and feasibility of MSC administration and reported some improvements, but other trials using larger cohorts of patients are needed. |
| first_indexed | 2024-03-10T14:48:11Z |
| format | Article |
| id | doaj.art-e4527725bb8946afbfed7cf1b42cbc54 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T14:48:11Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e4527725bb8946afbfed7cf1b42cbc542023-11-20T21:14:06ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-012122866210.3390/ijms21228662Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical StudiesAgnese Gugliandolo0Placido Bramanti1Emanuela Mazzon2IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyIRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyIRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyMultiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Nowadays, available therapies for MS can help to manage MS course and symptoms, but new therapeutic approaches are required. Stem cell therapy using mesenchymal stem cells (MSCs) appeared promising in different neurodegenerative conditions, thanks to their beneficial capacities, including the immunomodulation ability, and to their secretome. The secretome is represented by growth factors, cytokines, and extracellular vesicles (EVs) released by MSCs. In this review, we focused on studies performed on in vivo MS models involving the administration of MSCs and on clinical trials evaluating MSCs administration. Experimental models of MS evidenced that MSCs were able to reduce inflammatory cell infiltration and disease score. Moreover, MSCs engineered to express different genes, preconditioned with different compounds, differentiated or in combination with other compounds also exerted beneficial actions in MS models, in some cases also superior to native MSCs. Secretome, both conditioned medium and EVs, also showed protective effects in MS models and appeared promising to develop new approaches. Clinical trials highlighted the safety and feasibility of MSC administration and reported some improvements, but other trials using larger cohorts of patients are needed.https://www.mdpi.com/1422-0067/21/22/8662multiple sclerosismesenchymal stem cellspreclinical modelsclinical trials |
| spellingShingle | Agnese Gugliandolo Placido Bramanti Emanuela Mazzon Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies International Journal of Molecular Sciences multiple sclerosis mesenchymal stem cells preclinical models clinical trials |
| title | Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies |
| title_full | Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies |
| title_fullStr | Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies |
| title_full_unstemmed | Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies |
| title_short | Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies |
| title_sort | mesenchymal stem cells in multiple sclerosis recent evidence from pre clinical to clinical studies |
| topic | multiple sclerosis mesenchymal stem cells preclinical models clinical trials |
| url | https://www.mdpi.com/1422-0067/21/22/8662 |
| work_keys_str_mv | AT agnesegugliandolo mesenchymalstemcellsinmultiplesclerosisrecentevidencefrompreclinicaltoclinicalstudies AT placidobramanti mesenchymalstemcellsinmultiplesclerosisrecentevidencefrompreclinicaltoclinicalstudies AT emanuelamazzon mesenchymalstemcellsinmultiplesclerosisrecentevidencefrompreclinicaltoclinicalstudies |